HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive: To explore the possible mechanism by which activation of HIF1α confers chemoresistance to CML cells despite complete inhibition of Bcr/Abl, changes in apoptosis-related gene expression were monitored in K562 and K562/HIF1α cells treated with Crizotinib.